Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Bursi · SciRah

Researcher profile · Semantic Scholar

S. Bursi

Share profile

S. Bursi — researcher profile on SciRah

h-index: 9
Works: 36
Citations: 356

Most-cited papers

Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
A. Fontana, L. Galli, A. Fioravanti, P. Orlandi +12 more
2009Clinical Cancer Research89 citations Open access
Semantic Scholar
Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction
Alice Alessandra Galeotti, M. Gentiluomo, C. Rizzato, O. Obazee +62 more
2020Journal of Medical Genetics57 citations Open access
Semantic Scholar
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
R. Marconcini, L. Galli, A. Antonuzzo, S. Bursi +4 more
2017Experimental Hematology & Oncology42 citations Open access
Semantic Scholar
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
E. Vasile, G. Masi, L. Fornaro, S. Cupini +11 more
2009British Journal of Cancer37 citations Open access
Semantic Scholar
METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER
A. Fontana, G. Bocci, L. Galli, M. D'Arcangelo +11 more
2010Journal of The American Geriatrics Society33 citations
Semantic Scholar
Genome‐wide association study identifies an early onset pancreatic cancer risk locus
D. Campa, M. Gentiluomo, O. Obazee, A. Ballerini +55 more
2020International Journal of Cancer27 citations Open access
Semantic Scholar
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
G. Masi, Lorenzo Marcucci, F. Loupakis, E. Cerri +9 more
2006Annals of Oncology27 citations Open access
Semantic Scholar
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
L. Fornaro, G. Masi, S. Bursi, F. Loupakis +8 more
2009Cancer Chemotherapy and Pharmacology17 citations
Semantic Scholar
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
G. Masi, E. Vasile, F. Loupakis, S. Bursi +5 more
2008Clinical colorectal cancer16 citations
Semantic Scholar
Consequences of targeted treatments for second-line therapy.
E. De Maio, C. Tibaldi, Armida D'Incecco, S. Bursi +7 more
2010Annals of Oncology5 citations Open access
Semantic Scholar
Early nutrition protocol during Covid-19 pandemic
S. Bursi, L. Esposito, F. Anzolin, S. Natale +4 more
2020Clinical Nutrition ESPEN2 citations Open access
Semantic Scholar
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
G. Masi, S. Bursi, F. Loupakis, M. Barletta +6 more
20072 citations
Semantic Scholar
3022 POSTER Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases
G. Masi, S. Bursi, F. Loupakis, C. Barbara +6 more
20071 citations
Semantic Scholar
3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo +6 more
20071 citations
Semantic Scholar
EARLY NUTRITION PROTOCOL FOR IN- AND OUT-PATIENTS DURING COVID-19 PANDEMIC
S. Bursi, F. Anzolin, S. Natale, G. Onfiani +4 more
2021Nutrition (Burbank, Los Angeles County, Calif.)0 citations Open access
Semantic Scholar
Body composition assessment in patients undergoing radiotherapy for head and neck cancer
S. Bursi, L. Esposito, F. Anzolin, L. Andrini +3 more
2020Clinical Nutrition ESPEN0 citations
Semantic Scholar
A multifactorial score for pancreatic ductal adenocarcinoma risk prediction
M. Gentiluomo, Alice Alessandra Galeotti, C. Rizzato, O. Obazee +62 more
2019Pancreatology (Print)0 citations
Semantic Scholar
SLC22A3 polymorphisms may influence overall patient survival- PANDORA study
B. Mohelníková-Duchoňová, Ondřej Strouhal, D. Hughes, M. Loveček +37 more
2018Pancreatology (Print)0 citations
Semantic Scholar
Phase II clinical trial with pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): preliminary clinical results
L. Derosa, M. D'Arcangelo, L. Galli, A. Fontana +9 more
20100 citations
Semantic Scholar
Cancer Therapy : Clinical Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide , Celecoxib , and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
A. Fontana, L. Galli, A. Fioravanti, P. Orlandi +12 more
20090 citations
Semantic Scholar
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts).
A. Fontana, G. Bocci, L. Galli, L. Derosa +6 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
L. Galli, A. Fontana, L. Derosa, G. Minuti +10 more
20090 citations
Semantic Scholar
7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)
A. Fontana, L. Galli, L. Derosa, G. Minuti +6 more
20090 citations
Semantic Scholar
Docetaxel-prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation
A. Fontana, L. Galli, L. Derosa, G. Minuti +12 more
20090 citations
Semantic Scholar
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC)
A. Fontana, G. Bocci, M. D'Arcangelo, L. Galli +13 more
20080 citations
Semantic Scholar
Retrospective analysis of concomitant treatment with 3-dimensional conformal radiotherapy and temozolomide in high-grade glioma patients
L. Landi, A. Fontana, C. Galli, L. Galli +10 more
20080 citations
Semantic Scholar
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
A. Fontana, G. Bocci, M. D'Arcangelo, L. Galli +6 more
20080 citations
Semantic Scholar
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study
A. Falcone, M. Andreuccetti, S. Ricci, C. Orlandini +11 more
20070 citations
Semantic Scholar
3051 POSTER Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
S. Cupini, S. Bursi, G. Masi, F. Loupakis +6 more
20070 citations
Semantic Scholar
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
S. Cupini, S. Bursi, G. Masi, F. Loupakis +12 more
20070 citations
Semantic Scholar
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report
M. Barletta, G. Bocci, F. Loupakis, A. Fioravanti +12 more
20070 citations
Semantic Scholar
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts)
G. Masi, F. Loupakis, S. Bursi, C. Barbara +13 more
20070 citations
Semantic Scholar
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo +14 more
20070 citations
Semantic Scholar
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group
S. Bursi, G. Masi, F. Loupakis, A. Antonuzzo +11 more
20070 citations
Semantic Scholar
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL)
S. Cupini, E. Capochiani, S. Bursi, L. Landi +15 more
20070 citations
Semantic Scholar
Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.)
S. Bursi, G. Masi, A. Antonuzzo, E. Cerri +14 more
20060 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Falcone×23
Invite
A. Falcone — researcher profile on SciRah
G. Masi×16
Invite
G. Masi — researcher profile on SciRah
A. Antonuzzo×15
Invite
A. Antonuzzo — researcher profile on SciRah
F. Loupakis×15
Invite
F. Loupakis — researcher profile on SciRah

×13

Invite

G. Allegrini — researcher profile on SciRah

Invite

L. Landi — researcher profile on SciRah

Invite

G. Bocci — researcher profile on SciRah

Invite

L. Galli — researcher profile on SciRah

M. Andreuccetti×10

Invite

M. Andreuccetti — researcher profile on SciRah

M. Barletta×10

Invite

M. Barletta — researcher profile on SciRah

Invite

C. Barbara — researcher profile on SciRah

Invite

S. Cupini — researcher profile on SciRah